Is CG a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for The Carlyle Group (CG) rests on Fee-related earnings and the shift toward permanent capital: Record FRE of ~$358 million in Q2 2026 at a ~47% margin is the metric management has organised the firm around, because it is the part of the P&L that does not require an exit to materialise. The bear case rests on fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash. Analysts covering it publish targets from $40.00 to $73.00 against a $38.62 share price on November 16, 2026, so even the professionals disagree by 66% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

CG key stats

At $38.62 on November 16, 2026, The Carlyle Group (CG) has a market cap of $13.7B, a P/E of 40.7 on trailing earnings (7.9 on forward earnings) and a dividend yield of 3.63%. It next reports earnings around February 4, 2027 (estimated).

Market cap
$13.7B
P/E (trailing)
40.7
P/E (forward)
7.9
EPS (trailing 12 months)
$0.95
Price to book
2.7
Dividend yield
3.63%
Beta
1.83
Next earnings
around February 4, 2027 (estimated)

Market cap, P/E and yield are measured at the $38.62 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with The Carlyle Group (CG)?

The last two weeks for The Carlyle Group, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • CG closed at $38.62 on November 16, 2026, down 8.7% over the past five trading days (from $42.31).
  • The Carlyle Group next reports quarterly results around February 4, 2027 (estimated).
  • On November 6, 2026, The Carlyle Group filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, The Carlyle Group filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 10, 2026, UBS lowered its target to $47.00 from $60.00 (Neutral).
  • On November 9, 2026, JP Morgan lowered its target to $62.00 from $64.00 (Neutral).
  • On November 6, 2026, Barclays lowered its target to $48.00 from $53.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Founded in 1987 and public since May 2012, Carlyle raises money from pension funds, sovereign wealth funds, insurers and, increasingly, individual investors, then deploys it across three reporting segments: Global Private Equity (buyouts, real assets, growth), Global Credit (direct lending, opportunistic credit, asset-backed finance, insurance solutions) and Carlyle AlpInvest (fund-of-funds, secondaries and co-investment, ~$112 billion of AUM on its own). About 2,500 employees work from 28 offices on four continents. Revenue arrives in three distinct shapes that behave nothing alike: recurring management fees charged on fee-earning capital, performance fees or carried interest recognised when funds exit investments above a hurdle, and principal investment income from the firm's own capital committed alongside clients. GAAP revenue therefore swings violently, from ~$3.0 billion in 2023 to ~$5.4 billion in 2024, which is why alternative managers report fee-related earnings and distributable earnings instead. Q2 2026 was among the strongest quarters Carlyle has posted since the 2021 boom. Fee-related earnings hit a record ~$358 million, up ~11% year over year at roughly a 47% margin, while distributable earnings of ~$472 million, or ~$1.07 per share after tax, were the highest in nearly four years and beat consensus near ~$0.94. Realisation activity did the heavy lifting: the firm returned ~$7 billion to fund investors in the quarter and ~$37 billion over the trailing year, and organic inflows of ~$30 billion in the first half were a company record. Markets have not rewarded it, and since the report they have moved further the other way. Shares closed at $37.00 on October 16, 2026, down ~39% year to date, ~35% over one year and ~17% over three months, close to a 52-week low of ~$35.41 and far below the ~$67.30 high. That puts the stock at a trailing P/E near ~38 on depressed GAAP earnings but a forward multiple of only ~7.4 on 2027 estimates. Capital returns continue through a ~$0.35 quarterly dividend, ~$1.40 annualised, which now yields ~3.8%, plus ~$304 million of buybacks in the second quarter. The autumn slide has come in steps. Analysts cut targets into the third quarter, with RBC moving to ~$48 from ~$58 and Wells Fargo starting coverage at Equalweight with a ~$43 target in early October. On October 9, 2026 Reuters reported that Carlyle was no longer actively pursuing Lukoil's ~$22 billion portfolio of international assets, a deal it had agreed to in January. On October 14 the shares fell ~3.4% as hotter-than-expected September inflation (consumer prices up 3.7% year over year) revived talk of further Federal Reserve hikes, a backdrop that slows private equity exits. Third quarter results are due November 4, 2026, with consensus distributable EPS near ~$1.00.

The bull case: what would have to be true for $73.00

The most optimistic published target on CG is $73.00, +89.0% from the $38.62 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. Fee-related earnings and the shift toward permanent capital

Record FRE of ~$358 million in Q2 2026 at a ~47% margin is the metric management has organised the firm around, because it is the part of the P&L that does not require an exit to materialise. Perpetual capital AUM reached ~$113 billion, up ~12% year over year, and pending fee-earning AUM of ~$28 billion rose ~57%, which is fee revenue already contracted but not yet switched on. Every dollar that migrates from drawdown funds toward perpetual vehicles makes the fee base less dependent on the next fundraise.

2. Credit and AlpInvest as second and third engines

For the first time, Global Credit and Carlyle AlpInvest both posted record distributable earnings in the same quarter, with AlpInvest contributing ~$96 million on ~$112 billion of AUM that grew ~16% year over year. Secondaries and co-investment carry lower performance-fee volatility than flagship buyout funds, and asset-backed finance plus insurance mandates such as the ~$5 billion Unum reinsurance block with Fortitude Re extend the credit franchise. Diversification away from a single realisation cycle is the explicit thesis CEO Harvey Schwartz has been selling since 2023.

3. The realisation cycle restarting

Carry only converts to cash when funds sell assets, and Carlyle distributed ~$7 billion in Q2 2026 and ~$37 billion across the trailing twelve months. US buyout returned ~23% of fair value to investors over that period, which management frames as roughly double the industry pace. A durable reopening of M&A and IPO exit routes would unlock net accrued performance revenue that currently sits on the balance sheet as an unrealised mark. The rate backdrop has turned less helpful since: by mid-October 2026 traders were pricing a meaningful chance of another Federal Reserve hike, and higher policy rates raise portfolio-company interest costs and tend to slow exits.

4. Wealth distribution and the fundraising super cycle

Evergreen AUM aimed at individual investors passed ~$20 billion, supported by distribution partnerships with AllianceBernstein in defined contribution and SEI on collective investment trusts. Management has publicly framed the next stretch as a fundraising super cycle targeting roughly ~$200 billion, alongside a new middle-market defence and industrials platform that opened with the acquisition of encryption provider Secturion Systems. Whether retail and insurance channels can offset slower institutional commitments is the single largest swing factor in the fee base over the next few years.

The bear case: what would have to be true for $40.00

The most pessimistic published target is $40.00, +3.6% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks The Carlyle Group is worth if the risks below bite instead of the drivers above.

Fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash. Performance fees are inherently lumpy and unrealised carry is a mark, not money, meaning distributable earnings can fall by half in a quiet quarter without anything fundamental breaking. Higher-for-longer rates raise financing costs across portfolio companies and compress private-market valuations, while heavy competition for direct lending assets pressures credit spreads. On the legal side, a Delaware fiduciary-duty suit brought by a pension fund against co-founders William Conway, Daniel D'Aniello and David Rubenstein and other directors over a ~$344 million payment to terminate the firm's tax receivable agreement was allowed to proceed in 2024 and remains a derivative matter rather than a securities-fraud class action; no active securities-fraud class action against Carlyle was identified as of October 2026. Regulators in the US and Europe continue to scrutinise fee disclosure, valuation practices and the push of illiquid strategies into retail and retirement channels, which is precisely where much of the growth plan sits. Large transactions can also slip away: Carlyle stepped back from the Lukoil international asset purchase in October 2026, months after agreeing to it, which shows how sanctions and politics can redirect deployment plans.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CG already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on CG

19 analysts cover CG, with an average target of $50.16 (+29.9% against $38.62) and a split of 10 buy, 9 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the CG forecast and price target page.

How is CG valued?

Market cap, P/E and dividend yield at today's price are in the CG key stats above. The business figures below come from The Carlyle Group's reported results as of October 2026 and change when it next reports.

  • Total AUM: ~$485B as of June 30, 2026, up ~4% year over year
  • Fee-related earnings (Q2 2026): ~$358M, a record, up ~11% YoY at a ~47% margin
  • Distributable earnings (Q2 2026): ~$472M, or ~$1.07 per share after tax, above consensus
  • GAAP revenue / net income (TTM): ~$2.8B / ~$364M
  • Dividend: ~$0.35 per quarter, ~$1.40 annualised, ~3.8% yield
  • Q3 2026 consensus (Nov 4): Distributable EPS ~$1.00

As of October 2026: GAAP earnings and the multiples built on them are close to meaningless for this business in isolation, because principal investment marks and consolidated fund accounting dominate the reported line; trailing GAAP revenue of ~$2.8 billion is down sharply even though fee-related earnings set a record. The gap between a ~38 trailing multiple and a ~7.4 forward multiple is the market pricing in that distortion and, after a ~39% fall this year, a heavy discount for exit timing and rate risk. The mean analyst target of ~$52.50 sits well above the October 16 price, but recent target cuts point the other way, and the November 4 report is the next read on realisations and fundraising.

How do you decide if CG is a buy?

Whether CG is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold CG indirectly through an index or sector ETF before adding more.

What would change your mind on CG

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: Fee-related earnings and the shift toward permanent capital stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the CG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CG against your real portfolio and see your actual exposure before deciding.

Your questions about The Carlyle Group

Ask Walnut's AI anything about CG and see how it fits what you own.

FAQ

Is CG a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on Fee-related earnings and the shift toward permanent capital, with gaap revenue / net income (ttm) at ~$2.8B / ~$364M. The bear case rests on fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash. Analysts covering it are spread from $40.00 to $73.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell CG?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $40.00, +3.6% from the $38.62 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for CG?

+

Fee-related earnings and the shift toward permanent capital. Record FRE of ~$358 million in Q2 2026 at a ~47% margin is the metric management has organised the firm around, because it is the part of the P&L that does not require an exit to materialise. The most optimistic analyst target on CG is $73.00, +89.0% from the $38.62 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for CG?

+

Fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash. Performance fees are inherently lumpy and unrealised carry is a mark, not money, meaning distributable earnings can fall by half in a quiet quarter without anything fundamental breaking. Higher-for-longer rates raise financing costs across portfolio companies and compress private-market valuations, while heavy competition for direct lending assets pressures credit spreads. On the legal side, a Delaware fiduciary-duty suit brought by a pension fund against co-founders William Conway, Daniel D'Aniello and David Rubenstein and other directors over a ~$344 million payment to terminate the firm's tax receivable agreement was allowed to proceed in 2024 and remains a derivative matter rather than a securities-fraud class action; no active securities-fraud class action against Carlyle was identified as of October 2026. Regulators in the US and Europe continue to scrutinise fee disclosure, valuation practices and the push of illiquid strategies into retail and retirement channels, which is precisely where much of the growth plan sits. Large transactions can also slip away: Carlyle stepped back from the Lukoil international asset purchase in October 2026, months after agreeing to it, which shows how sanctions and politics can redirect deployment plans. The most pessimistic published target is $40.00, +3.6% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does The Carlyle Group do?

+

Founded in 1987 and public since 2012, Carlyle manages roughly $485 billion across private equity, credit and its AlpInvest secondaries arm.

What would have to change for CG to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Fee-related earnings and the shift toward permanent capital) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (fundraising is cyclical and reflexive, so a stretch of weak fund performance or a closed exit window can shrink fee-earning AUM at the same moment carried interest stops converting to cash) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What company trades under the ticker CG?

+

CG is The Carlyle Group Inc., an alternative asset manager headquartered in Washington, DC and listed on the Nasdaq Global Select Market since its May 2012 IPO. It is a US operating company with ~2,500 employees and ~$485 billion of assets under management, not a fund or a trust.

How do you invest in Carlyle Group stock?

+

Shares trade on the Nasdaq under CG and can be bought through any brokerage that handles US listed equities, including fractional purchases at brokers that support them. Owning CG is different from investing in a Carlyle fund: shareholders own the management company and its share of fees and carry, while the underlying private-equity funds remain restricted to qualified institutional and accredited investors.

Walnut is informational, not investment advice, and gives no verdict on CG. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks